250-mg regimen compared with 7%0 of 67 men on the 500-mg regimen; x2 = 4 45, P<0 05). Failure occurred more frequently in men who were initially chlamydia-negative and in men in whom U urealyticum persisted after medication. Thus, the 250-mg regimen appeared to be as effective as the 500-mg regimen in the initial treatment of NGU. However, one-third of men had persistent or recurrent urethritis with these regimens, and there is a need for antimicrobial agents with greater in-vivo activity, especially against chlamydia-negative NGU.
Introduction
One standard treatment for nongonococcal urethritis (NGU) is tetracycline hydrochloride 500 mg four times daily for seven days. A previous study showed that minocycline 100 mg once daily for seven days was as effective as 100 mg twice daily for seven days (or 100 mg once or twice daily for 21 days).' Thus, a lower dose of tetracycline than 500 mg four times daily might be equally effective. This would be less expensive and would possibiy produce fewer side effects. Consequently, in this study the results with tetracycline 250 mg four times daily for seven days (250-mg regimen) were compared with those with tetracycline hydrochloride 500 mg four times daily for seven days (500-mg regimen) in the treatment of NGU.
Previous studies with tetracyclines have shown that chlamydia-positive NGU responds better to treatment than chlamydia-negative NGU. 1 Men were randomly assigned to either the 250-mg or the 500-mg (four times daily for seven days) treatment regimens. The men and the clinicians, but not the laboratory staff, knew which dose was being received. The men were asked to return for follow up at 10, 21, and 42 days after the start of therapy. They arrived for these visits when they had not voided for at least four hours. They were questioned about symptomatology, side effects of therapy, and interim sexual activity and were examined for urethral 333 discharge. A urethrogenital swab was inserted 1-2 cm beyond the fossa navicularis for chlamydial cultures; the first-voided urine was examined for trichomonads and PMNL and cultured quantitatively for U urealyticum.
Response to treatment was divided into four categories: (1) pyuria, plus a purulent or profuse mucoid discharge, between 21±7 and 42±7 days after the start of treatment was called NGU; (2) pyuria with no, or minimal, non-purulent discharge which was present at 42 ± 7 days after the start of therapy was called urine failure (both men with NGU and urine failure were called treatment failures); (3) pyuria with no, or minimal, non-purulent discharge at some time seven or more days after the start of treatment but which cleared by 42 ± 7 days after the start of treatment was called slow response; and (4) no pyuria and no, or minimal, non-purulent discharge with follow up for 42±7 days after the start of treatment was called normal (men who were normal or had a slow response were called responders).
STATISTICS
The proportions of groups affected by selected variables were compared by the x2 test with Yates's correction.7
Results

ISOLATION
Two hundred men fulfilled the criteria for the study. There were no significant differences in the initial isolation rates for patients given the two regimens. The initial isolation rates for C trachomatis and U urealyticum are shown in table I according to sexual preference. Overall, C trachomatis was isolated from 40%7o and U urealyticum from 48% of patients. Eight of 10 homosexual men compared with 39 (21%) of 190 bisexual or heterosexual men had negative culture results for both C trachomatis and U urealyticum (x = -5 5, P<0-0005). *Both doses of tetracycline were given four times daily for seven days.
C + = C trachomatis-positive; C -= C trachomatis-negative U + = U urealyticum-positive; U -= U urealyticum-negative 
Discussion
This randomised, but not double-blind, study has shown that the 250-mg regimen of tetracycline is as effective in eradicating C trachomatis and U urealyticum as the 500-mg regimen, and that by six 335 weeks after the start of treatment both regimens were associated with persistence or recurrence of NGU in one-third of the men studied. It was previously shown that minocycline 100 mg once daily for seven days eradicated C trachomatis and produced similar clinical results by six weeks after treatment as 100 mg twice daily for seven days, and 100 mg once or twice daily for 21 days.' Thus the results in this study are not unexpected. They leave unanswered the question whether or not even lower doses or, better still, less frequent doses of tetracycline will be equally effective. Side effects were not a problem with either dose of tetracycline in the men in this study.
The importance of U urealyticum as a urethral pathogen remains uncertain. Although there are some contradictory data, there is mounting evidence that U urealyticum is a urethral pathogen. In three recent studies in Seattle' 89 and a study in San Francisco,'0 U urealyticum was isolated more often from chlamydia-negative compared with chlamydiapositive men. Persistence of U urealyticum after treatment with sulphonamides,8 9 aminocyclitols, rifampicin," low-dose tetracycline, 12 and minocycline' is associated with a higher failure rate. Intraurethral inoculation of primates'3 and humans'4 is associated with urethritis. Thus, the higher rate of isolation of U urealyticum from chlamydia-negative men, and the presence of pyuria and a purulent or profuse mucoid discharge in a greater proportion of initially U urealyticum-positive men with persistent U urealyticum at follow up compared with men in whom U urealyticum was eradicated further supports the importance of U urealyticum as a urethral pathogen in some men from whom it is initially isolated.
The higher rate of NGU at follow up in men with persistent U urealyticum could be artifactual since only first-voided urine samples were cultured. In men with urethritis, intraurethreal swabs and first-voided urine samples yield similar rates of isolation of U urealyticum (W R Bowie, unpublished data). In some studies of men without urethritis however swabs were reported to yield U urealyticum more often than urine specimens. 15 
